Company intelligence
Cadila Pharmaceuticals Limited
The Care Continues...
About Cadila Pharmaceuticals Limited
Founded by Shri I.A. Modi, Cadila Pharmaceuticals Ltd. is one of the largest privately held pharmaceutical companies in India, headquartered at Ahmedabad, in the State of Gujarat. Over the last seven decades, the company has been developing and manufacturing pharmaceutical products in India and selling and distributing these in over hundred other countries around the world. Focused strongly on Innovation and Research, the company is present in more than forty-five therapeutic areas spread across twelve specialities, including cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives and antibiotics, respiratory agents, antidiabetics and immunologicals. At Cadila Pharmaceuticals, Research and Development is at the core of all its initiatives, be it Biotechnology, APIs, Formulations, Plant Tissue Culture or Phytochemistry. More than 300 scientists in its various Research and Development setups reinforce the competitiveness of research in the therapeutic areas which have high unmet medical needs. Cadila Pharmaceuticals Excellence in manufacturing facilities is central to Cadila Pharmaceuticals. The company’s formulations manufacturing plant at Dholka near Ahmedabad, Gujarat is spread over hundred acres of land. This state-of-the- art facility is not only impressive in size, but is also USFDA approved. The second formulations manufacturing facility is located at Samba in Jammu and Kashmir. The facility meets most of the stringent quality standards across the globe to produce tablets, capsules, soft and hard gelatin capsules, liquids and orals. Two Active Pharmaceutical Ingredient (API) manufacturing units at Ankleshwar, Gujarat manufacture a wide range of APIs and intermediates including many USFDA-certified products. The company has strong foothold in the African continent through its formulation manufacturing facility at Addis Ababa in Ethiopia. For more information visit: https://www.cadilapharma.com/
Verified activity
Signals from Cadila Pharmaceuticals Limited
6 published signals
Presence & Recognition
Cadila Pharmaceuticals Limited welcomed a delegation from the Krasnodar Region, Russia, to the Dholka manufacturing facility in Ahmedabad on 8 September 2026.
Reported by Cadila Pharmaceuticals Limited
Presence & Recognition
Cadila Pharmaceuticals Limited announced that Vice President Brijeshkumar Mayani will be attending CPhI Milan 2026 at Fiera Milano, Italy, from 6 to 8 October 2026 to explore opportunities across Licensing, CMO, M&A, and Global Institutional Business.
Reported by Cadila Pharmaceuticals Limited
Presence & Recognition
Cadila Pharmaceuticals Limited announced that Mr. Vikas Khatri, President and Global Chief Business Officer (CDMO/CMO), will be attending CPhI Milan 2026 at Fiera Milano, Italy from 6 to 8 October 2026.
Reported by Cadila Pharmaceuticals Limited
Presence & Recognition
Cadila Pharmaceuticals Limited engaged in a bilateral meeting with Mr. Abdulla Azizov, Chairman–First Deputy Minister of Health, Republic of Uzbekistan, during the India–Uzbekistan Forum in New Delhi on 5 August 2026.
Reported by Cadila Pharmaceuticals Limited
Presence & Recognition
Cadila Pharmaceuticals Limited hosted Mr. Samar Ghosh, Global Head – Strategy, at CPhI Milan 2026 for strategic conversations around sustainable growth, innovation, business transformation, and long-term value creation.
Reported by Cadila Pharmaceuticals Limited
Presence & Recognition
Cadila Pharmaceuticals Limited announced that Ajay Vale, President – International Business, will be attending CPhI Milan 2026 at Fiera Milano, Italy from 6 to 8 October 2026.
Reported by Cadila Pharmaceuticals Limited